Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
About this episode
Dr Hanny Al-Samkari discusses recent developments in the treatment of immune thrombocytopenia from the ASH 2025 Annual Meeting.
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia. CME information and select publications here .
More episodes of Hematologic Oncology Update
- Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
- CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
- Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
- CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
- CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
- Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting
Explore listener stats, chart rankings, contacts and more on the Hematologic Oncology Update podcast page.